[New long-acting treatment of anxiety and its different forms of somatization: low-dose fluspirilene].
After pharmacological considerations on fluspirilene, a diphenylbutylpiperidinic neuroleptic with a tranquillizing action in neurotic syndromes, the Authors refer on 24 patients with a normal social behaviour treated with low dosage. I.M. weekly dosages of 1.5 mg have been used for 6 weeks with semi-quantitative evaluation of 1-5 psychic items, 10 neurovegetative items and 36 miscellaneous. A significant improvement was obtained for nearly all symptoms and did not cause variations in bodyweight, pressure values and pulse frequency or local or systemic intolerance. Positive results reached 77.3% of treated cases, in agreement with those reported by numerous foreign Authors.
D000293:Adolescent; D000328:Adult; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003866:Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D004341:Drug Evaluation; D005260:Female; D005484:Fluspirilene / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011602:Psychophysiologic Disorders / Q000188:drug therapy* / Q000523:psychology; D011674:Pulse / Q000187:drug effects; D013141:Spiro Compounds / Q000008:administration & dosage*; D013997:Time Factors
D013141:Spiro Compounds; D005484:Fluspirilene
Un nuovo trattamento long-acting dell'ansia e delle differenti forme della sua somatizzazione: fluspirilene low-dose.